Viking Therapeutics: The Market Might Shrug Off The Maintenance Data (NASDAQ:VKTX)
· seekingalpha.com
VKTX stock outlook: VK2735 obesity/diabetes catalyst timeline, oral vs injectable differentiation, cash burn & dilution risk.
Viking Therapeutics ( VKTX ) is continuing on with its development of VK2735, an incretin with potential for weight loss and diabetes, among other indications. ...